Phase Ib/II Study of ABBV-927 Administered in Combination With Modified FOLFIRINOX (mFFX) With or Without Budigalimab Compared to mFFX in Patients with Untreated Metastatic Pancreatic Adenocarcinoma
Summary
The purpose of this phase Ib/II trial is to evaluate the safety and feasibility of modified FOLFIRINOX combined with IV infusions of ABB-927 with or without Budigalimab (ABBV-181) in patients with untreated metastatic pancreatic cancer.
General Information
NCT#: NCT04807972
Study ID: M20-732
Trial Phase: Phase II
Trial Sponsor: AbbVie
Therapies Used in This Trial: FOLFIRINOX, ABBV-927, Budigalimab